Back to Search Start Over

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

Authors :
Merve Hasanov
Denái R Milton
Alicia Bea Davies
Elizabeth Sirmans
Chantal Saberian
Eliza L Posada
Sylvia Opusunju
Jeffrey E Gershenwald
Carlos A Torres-Cabala
Elizabeth M Burton
Rivka R Colen
Jason T Huse
Isabella C Glitza Oliva
Caroline Chung
Mary Frances McAleer
Susan L McGovern
Debra N Yeboa
Betty Y S Kim
Sujit S Prabhu
Ian E McCutcheon
Jeffrey S Weinberg
Frederick F Lang
Hussein A Tawbi
Jing Li
Lauren E Haydu
Michael A Davies
Sherise D Ferguson
Source :
Neuro-Oncology.
Publication Year :
2022
Publisher :
Oxford University Press (OUP), 2022.

Abstract

Background Treatment options for patients with melanoma brain metastasis (MBM) have changed significantly in the last decade. Few studies have evaluated changes in outcomes and factors associated with survival in MBM patients over time. The aim of this study is to evaluate changes in clinical features and overall survival (OS) for MBM patients. Methods Patients diagnosed with MBMs from 1/1/2009 to 12/31/2013 (Prior Era; PE) and 1/1/2014 to 12/31/2018 (Current Era; CE) at The University of Texas MD Anderson Cancer Center were included in this retrospective analysis. The primary outcome measure was OS. Log-rank test assessed differences between groups; multivariable analyses were performed with Cox proportional hazards models and recursive partitioning analysis (RPA). Results A total of 791 MBM patients (PE, n = 332; CE, n = 459) were included in analysis. Median OS from MBM diagnosis was 10.3 months (95% CI, 8.9–12.4) and improved in the CE vs PE (14.4 vs 10.3 months, P Conclusions OS and factors associated with OS have changed for MBM patients. This information can inform contemporary patient management and clinical investigations.

Details

ISSN :
15235866 and 15228517
Database :
OpenAIRE
Journal :
Neuro-Oncology
Accession number :
edsair.doi.dedup.....a9f942ee1df43acd5f1b8df51355b63b